Standard Biotools Current Valuation
| LAB Stock | USD 1.24 0.02 1.59% |
Valuation analysis of Standard Biotools helps investors to measure Standard Biotools' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of February 11, 2026, Enterprise Value Over EBITDA is expected to decline to -3.87. In addition to that, Enterprise Value Multiple is expected to decline to -3.87. Fundamental drivers impacting Standard Biotools' valuation include:
Undervalued
Today
Please note that Standard Biotools' price fluctuation is dangerous at this time. Calculation of the real value of Standard Biotools is based on 3 months time horizon. Increasing Standard Biotools' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Standard Biotools is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Standard Stock. However, Standard Biotools' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.24 | Real 1.34 | Target 1.55 | Hype 1.24 |
The real value of Standard Stock, also known as its intrinsic value, is the underlying worth of Standard Biotools Company, which is reflected in its stock price. It is based on Standard Biotools' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Standard Biotools' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Standard Biotools helps investors to forecast how Standard stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Standard Biotools more accurately as focusing exclusively on Standard Biotools' fundamentals will not take into account other important factors: Standard Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Standard Biotools is extremely important. It helps to project a fair market value of Standard Stock properly, considering its historical fundamentals such as Current Valuation. Since Standard Biotools' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Standard Biotools' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Standard Biotools' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. Expected growth trajectory for Standard significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Standard Biotools assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.39) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Standard Biotools' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Standard Biotools represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Standard Biotools' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Standard Biotools 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Standard Biotools' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Standard Biotools.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Standard Biotools on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Standard Biotools or generate 0.0% return on investment in Standard Biotools over 90 days. Standard Biotools is related to or competes with Varex Imaging, CeriBell, Cullinan Oncology, Avanos Medical, So Young, ADC Therapeutics, and Treace Medical. Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researche... More
Standard Biotools Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Standard Biotools' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Standard Biotools upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.6 | |||
| Information Ratio | 0.0286 | |||
| Maximum Drawdown | 25.5 | |||
| Value At Risk | (5.33) | |||
| Potential Upside | 7.81 |
Standard Biotools Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Standard Biotools' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Standard Biotools' standard deviation. In reality, there are many statistical measures that can use Standard Biotools historical prices to predict the future Standard Biotools' volatility.| Risk Adjusted Performance | 0.0482 | |||
| Jensen Alpha | 0.1004 | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | 0.0344 | |||
| Treynor Ratio | 0.1609 |
Standard Biotools February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0482 | |||
| Market Risk Adjusted Performance | 0.1709 | |||
| Mean Deviation | 2.98 | |||
| Semi Deviation | 3.22 | |||
| Downside Deviation | 3.6 | |||
| Coefficient Of Variation | 2000.52 | |||
| Standard Deviation | 4.33 | |||
| Variance | 18.74 | |||
| Information Ratio | 0.0286 | |||
| Jensen Alpha | 0.1004 | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | 0.0344 | |||
| Treynor Ratio | 0.1609 | |||
| Maximum Drawdown | 25.5 | |||
| Value At Risk | (5.33) | |||
| Potential Upside | 7.81 | |||
| Downside Variance | 12.96 | |||
| Semi Variance | 10.35 | |||
| Expected Short fall | (3.86) | |||
| Skewness | 1.48 | |||
| Kurtosis | 6.53 |
Standard Biotools Backtested Returns
At this point, Standard Biotools is dangerous. Standard Biotools owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0335, which indicates the firm had a 0.0335 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Standard Biotools, which you can use to evaluate the volatility of the company. Please validate Standard Biotools' Semi Deviation of 3.22, coefficient of variation of 2000.52, and Risk Adjusted Performance of 0.0482 to confirm if the risk estimate we provide is consistent with the expected return of 0.15%. Standard Biotools has a performance score of 2 on a scale of 0 to 100. The entity has a beta of 1.28, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. Standard Biotools right now has a risk of 4.5%. Please validate Standard Biotools jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to decide if Standard Biotools will be following its existing price patterns.
Auto-correlation | 0.19 |
Very weak predictability
Standard Biotools has very weak predictability. Overlapping area represents the amount of predictability between Standard Biotools time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Standard Biotools price movement. The serial correlation of 0.19 indicates that over 19.0% of current Standard Biotools price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.19 | |
| Spearman Rank Test | -0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Standard Biotools has a Current Valuation of 317.04 M. This is 97.79% lower than that of the Life Sciences Tools & Services sector and 95.93% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.09% higher than that of the company.
Standard Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Standard Biotools' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Standard Biotools could also be used in its relative valuation, which is a method of valuing Standard Biotools by comparing valuation metrics of similar companies.Standard Biotools is currently under evaluation in current valuation category among its peers.
Standard Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 317.04 M | ||||
| Shares Outstanding | 384.57 M | ||||
| Shares Owned By Insiders | 2.57 % | ||||
| Shares Owned By Institutions | 77.20 % | ||||
| Number Of Shares Shorted | 9.79 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 2.85 X | ||||
| Revenue | 174.43 M | ||||
| Gross Profit | 81.9 M | ||||
| EBITDA | (118.14 M) | ||||
| Net Income | (138.88 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 33 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (143.45 M) | ||||
| Short Ratio | 5.66 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Price To Earnings To Growth | 0.31 X | ||||
| Target Price | 1.55 | ||||
| Number Of Employees | 814 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 484.55 M | ||||
| Total Asset | 612.34 M | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 309.99 M | ||||
| Net Asset | 612.34 M |
About Standard Biotools Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Standard Biotools's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Standard Biotools using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Standard Biotools based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. Expected growth trajectory for Standard significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Standard Biotools assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.39) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Standard Biotools' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Standard Biotools represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Standard Biotools' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.